NDA Group announces Christine Lind as the new VP of Commercial
Sweden – April 27, 2021 – Life Science Newswire – Christine Lind, joins NDA Group as Vice President of Commercial from her most recent role as Strategy and Business Development advisor to BioArctic AB. With over 20 years’ experience in a variety of roles within the Life Science sector, Christine’s track record of both team leadership and successful commercial transactions speaks for itself.
“The ability to have an impact is important to me”, says Christine.” I chose the biotech/pharma sector as a focus, not because I am a scientist but because of how the industry contributes to patients and society. NDA’s mission to bring good products to the world is inspiring and resonates with me, and of course, I’ve learned from experience that the team is world class.”
The Vice President of Commercial drives a valuable function, connecting innovative companies with NDA’s expertise and services, whilst also considering and evaluating new opportunities for growth. This is an ideal match for Christine who has spent the last 10 years in executive leadership in biotech and medtech companies focusing on strategy and business development fueled growth.
“I am looking forward to working with Christine to further clarify the focus of NDA’s core service offerings and identify those companies that benefit the most from our support”, says Johan Strömquist, CEO NDA Group. “I especially think that her experience from leading a small biotech and understanding the challenges and key activities that are necessary to be successful in our industry will be tremendously valuable as we work to design and deliver services that can be truly transformational for our clients.”
“The pathway to product approval is extremely complex”, adds Christine. “This is why understanding the client’s needs and how to optimize the development plan to ensure the right path is important to overcome this challenge. I am looking forward to leading that team that can help by connecting our clients with the NDA experts who can make a real difference.”
For more information, please visit www.ndareg.com
About Christine Lind
Before joining NDA Christine worked as Strategy and Business Development advisor to BioArctic AB, a Swedish biotech company. Previously, she led the Swedish biotech company Medivir AB as their CEO and has served as head of business development at Medivir and at US medtech company, LifeCell Corporation, following a decade long career at global investment bank Merrill Lynch & Co. in their healthcare advisory group.
About NDA Group
NDA Group is a world-leading regulatory, drug development and medical device consultancy with offices in Boston, London, Munich, Paris, Princeton, San Francisco, Stockholm, and Zürich. Its mission is to ensure that good medicines reach patients without unnecessary delay. It accomplishes this by providing the pharmaceutical industry with a comprehensive range of professional drug and device development services focusing on regulatory affairs, health technology assessment, pharmacovigilance, and quality assurance. NDA’s dedicated team of more than 150 consultants is supported by an expert network and a specialist Advisory Board many of whom are ex- European and US Agency staff. The NDA Advisory Board provides scientific advice to pharmaceutical companies supporting them in gaining fast and constructive assessment of applications from regulatory agencies and HTA bodies.